United Therapeutics (UTHR) to Release Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is set to announce its earnings results before the market opens on Wednesday, May 1st. Analysts expect United Therapeutics to post earnings of $5.63 per share for the quarter.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. During the same quarter last year, the business posted $2.67 EPS. United Therapeutics’s revenue was up 25.1% on a year-over-year basis. On average, analysts expect United Therapeutics to post $23 EPS for the current fiscal year and $25 EPS for the next fiscal year.

United Therapeutics Stock Performance

United Therapeutics stock traded down $2.06 during trading hours on Thursday, reaching $234.94. 81,041 shares of the company were exchanged, compared to its average volume of 435,203. The stock has a 50-day moving average of $232.93 and a 200 day moving average of $228.74. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The firm has a market cap of $11.06 billion, a price-to-earnings ratio of 11.86 and a beta of 0.52. United Therapeutics has a 12 month low of $204.44 and a 12 month high of $261.54.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on UTHR shares. Wedbush restated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. Wells Fargo & Company lifted their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Finally, The Goldman Sachs Group raised shares of United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price target for the stock from $213.00 to $215.00 in a report on Monday, February 12th. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $294.25.

Insider Buying and Selling

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of $236.47, for a total transaction of $851,292.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,741.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $248.33, for a total transaction of $3,724,950.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at approximately $32,282.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $236.47, for a total transaction of $851,292.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,741.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 133,390 shares of company stock valued at $31,379,925. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.